| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.004 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.005 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.008 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |